| Popis: |
The evolution of aluminum (Al) serum levels was studied in 43 patients treated by CAPD during a 2 yr follow-up, with varying aluminum exposure. Serum levels and peritoneal transfer of Al were studied in 22 patients. Al concentration in the dialysis fluid was very low (range = 0.25 − 0.30 μmol/L). Patients were divided into three groups. Transfer of Al from the patient to the dialysate was observed in all patients. In group 1, patients exclusively treated by CAPD and who have never received aluminum-containing phosphate binders (ACPB), the mean serum Al concentration was stable in a safe normal range (0.60 ± 0.28 μ mol/L) with a very low peritoneal transfer. In group 2, the oral administration of ACPB in patients exclusively treated by CAPD induced a slow and progressive increase of serum Al concentration despite an increase in Al excretion through the peritoneal route. In group 3, patients previously treated by hemodialysis and receiving ACPB, the high serum Al levels before CAPD treatment were rapidly reduced on CAPD, with a higher removal of Al through the peritoneal membrane. |
